Cancilico raises €2.5M Seed round
20 January 2026· Dresden, Germany· health, diagnostics, biotech, ai, pure_software, b2b
The funding will accelerate Cancilico's mission to establish its AI-based diagnostic software MyeloAID as a routine tool, overcome regulatory hurdles (FDA and CE-IVDR), and accelerate digital biomarker development in hematological malignancies worldwide.
Investors
LeadHigh-Tech Gründerfonds
Also participating
GEDAD GmbHROI VerwaltungsgesellschaftTGFS Technologiegründerfonds Sachsen
About Cancilico
Stage
Seed
Headquarters
Dresden, Germany
Founded
2023
Team Size
6–20
Sectors
healthdiagnosticsbiotechaipure_softwareb2b